Torna ai risultati della ricercaBando per assegno di ricerca
| Titolo del progetto di ricerca in italiano | FATTORI CHE INFLUENZANO LA RISPOSTA AL TRATTAMENTO CON DARATUMUMAB NEI PAZIENTI AFFETTI DA MIELOMA MULTIPLO: IMMUNITA’ E IL MICROAMBIENTE |
|---|---|
| Titolo del progetto di ricerca in inglese | FACTORS THAT INFLUENCE THE RESPONSE TO DARATUMUMAB TREATMENT IN MULTIPLE MYELOMA PATIENTS: IMMUNITY AND MICROENVIRONMENT |
| Campo principale della ricerca | Medical sciences |
| Sottocampo della ricerca | Medicine |
| Area CUN | 06 - Scienze mediche |
| S.S.D | MED/15 - MALATTIE DEL SANGUE |
| Descrizione sintetica in italiano | Multiple Myeloma (MM) is a hematologic neoplasm characterized by the presence of tumoral plasma cells which produce a monoclonal immunoglobulin, whose accumulation induce organ damages and clinical symptoms as hypercalcemia, renal impairment, anaemia and bone lesions. New drugs improved the quality of response to therapy, elongating remission and survival of myeloma patients. The evolution of techniques for the evaluation of minimal residual disease (MRD), as next generation flow (NGF), permit a better quantification of the disease, and to recognize those patients able to achieve Complete Response. Daratumumab, a monoclonal antibody that binds to the CD38 receptor on monoclonal plasma cells, inducing their death by apoptosis, could be a good drug as a consolidation therapy; however, there is the need to clarify the mechanisms who might influence treatment response, such as the role of immunity or of the microenvironment in which tumour cells survive and proliferate |
| Descrizione sintetica in inglese | Multiple Myeloma (MM) is a hematologic neoplasm characterized by the presence of tumoral plasma cells which produce a monoclonal immunoglobulin, whose accumulation induce organ damages and clinical symptoms as hypercalcemia, renal impairment, anaemia and bone lesions. The evolution of techniques for the evaluation of minimal residual disease (MRD), as next generation flow (NGF), permit a better quantification of the disease, and to recognize those patients able to achieve Complete Response. Daratumumab, a monoclonal antibody binding the CD38 receptor on monoclonal plasma cells, inducing their death by apoptosis, could be a good drug as a consolidation therapy; however, there is the need to clarify the mechanisms who might influence treatment response, such as the role of immunity or of the microenvironment in which tumour cells survive and proliferate |
| Data del bando | 14/01/2022 |
| Numero di assegnazioni per anno | 1 |
| Paesi in cui può essere condotta la ricerca |
Italy |
| Paesi di residenza dei candidati |
OTHER |
| Nazionalità dei candidati |
OTHER |
| Sito web del bando | https://www.unisi.it |
| Destinatari dell'assegno di ricerca (of target group) |
Early stage researcher or 0-4 yrs (Post graduate) |
|---|
| Nome dell'Ente finanziatore | Università degli Studi di Siena |
|---|---|
| Tipologia dell'Ente | Public research |
| Paese dell'Ente | Italy |
| Città | Siena |
| Sito web | https://www.unisi.it/ |
| segr.dip.dsmcn@unisi.it | |
| Telefono | 0577- 235754- 235751 - 235755 |
| L'assegno finanziato/cofinanziato attraverso un EU Research Framework Programme? | No |
|---|
| Data di scadenza del bando | 03/02/2022 |
|---|---|
| Come candidarsi | segr.dip.dsmcn@unisi.it |